Oof, LYRA is a wild one! The news is pure rocket fuel with that 550% spike and positive Phase 3 data. 🚀 But the technicals are telling a different story – the stock is in a nasty comedown. The RSI is screaming oversold (under 20!), which often means the panic selling is exhausted. This looks like a classic "buy the dip" setup after a massive news-driven run. The fear is palpable, but the science is solid. BUY. #BiotechRollercoaster

"LYRA’s stock is a rollercoaster—Q1 miss, but a Strong Buy upgrade? 🤔 RSI is flirting with oversold (34), and volume spiked on that wild 90% drop. WMAs are bearishly crossed, but if their Phase 3 data at COSM 2025 surprises, this biotech could bounce. Chart’s messy, but news-driven volatility screams speculative PLAY, not a stable bet. High-risk, high-reward—grab popcorn or a seat. 🎢 #BiotechBets"

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

Lyra Therapeutics, Inc. LYRA: 4.27 USD

Bullish views